We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Microbiome Changes Reveal Risk for Sexually Transmitted Disease

Bacteria living the the gut.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 6 minutes

Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial infection. Now, researchers at Albert Einstein College of MedicineRoswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount Sinai have found that BV actually consists of two subtypes—one of which significantly increases the risk of developing chlamydia infections. The findings were made in a population of young Black and Hispanic women, who are disproportionately affected by both BV and chlamydia, but are historically understudied. The study, one of the largest and most comprehensive of its kind, was published online today in the journal Cell. 


It was already known that BV raises a womans risk for acquiring chlamydia, but it wasnt clear how the microbiome imbalances seen in BV contribute to that risk,” said study co-leader Robert Burk, M.D., professor of pediatrics, of microbiology & immunology, of obstetrics & gynecology and womens health, and of epidemiology & population health at Einstein and vice chair for translational research in the department of pediatrics at Montefiore EinsteinThis research shows that specific changes in the cervicovaginal microbiome set the stage for chlamydia. And it shows that targeting treatment against the more-dangerous BV subtype could potentially prevent many women from developing chlamydia, which is particularly prevalent in historically underserved communities.”  

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

BV affects at least 30% of women at any given time and up to 50% of Black and Hispanic women. Black and Hispanic adolescent and young adult females have a five-fold higher risk of acquiring chlamydia compared with their white counterparts. 


“This study was made possible by the participation of young women of color, who are at highest risk for this infection and most likely to experience its negative impact,” said study co-author Angela Diaz, M.D., Ph.D., MPH, dean of Global Health, Social Justice, and Human Rights at the Icahn School of Medicine at Mount Sinai. “We hope that our research and future studies continue to address disparities in healthcare, improve access to treatment, and enhance our approach to personalized care.” 

Discovering two types of BV infection 

BV is caused by imbalances in the cervicovaginal microbiome—the collection of bacteria naturally found in the genital tract. Common symptoms include vaginal discharge, itching or irritation, and burning sensation during urination, although many cases are asymptomatic. BV can be readily treated with antibiotics.  


In the new study, the researchers used advanced DNA-sequencing technology to analyze the cervicovaginal microbiomes of 560 adolescent and young adult Black and Hispanic females. The analyses were performed before infection with chlamydia, at the time of infection, and following antibiotic treatment, allowing the researchers to identify which combination of cervicovaginal bacteria is associated with subsequent chlamydia infections. 


The analysis detected two distinct subtypes of BV. One subtype—a collection of ten different interconnected bacterial types that account for about 40% of all BV cases—contributed to increased risk for acquiring chlamydia, subsequent reinfection with chlamydia, and complications such as pelvic inflammatory disease.  


“This study adds to the growing evidence of the impact of BV on the risk of clinically significant infections, including chlamydia and human papillomaviruses, that can cause cervical cancer,” said Nicolas Schlecht, Ph.D., M.Sc., professor of oncology at Roswell Park Comprehensive Cancer Center, noting in particular work published by this group of collaborators in Nature Communications in 2022. “It’s our hope that this work to reveal the connections between the cervicovaginal microbiome, common infections like chlamydia and HPV, and cancer might help advance the larger effort to prevent more cancers and other resulting conditions.” Dr. Schlecht, who was co-lead and co-author of the study, also serves as an adjunct faculty member at Einstein. 

Treating One Infection to Prevent Another 

These results are particularly significant for communities of color and could lead to a wholly new approach for clinically managing BV and chlamydia,” said Dr. Burk, who is also a clinical geneticist at the Childrens Hospital at Montefiore and a member of the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center We can now determine which BV cases are most worrisome and should be closely monitored. Detecting and treating these infections could substantially reduce the incidence of chlamydia and its serious consequences including pelvic inflammatory disease, infertility, and miscarriage. The findings also suggest that altering the cervicovaginal microbiome could be a strategy for both treating BV and preventing chlamydia.” 


Dr. Burk likens BV to high blood pressure. High blood pressure is silent, but its not harmless,” he said. We routinely screen for high blood pressure because its a major risk factor for cardiovascular disease. By the same token, BV is more or less silent but is a major risk factor for chlamydia. Regularly screening for and treating BV would go a long way toward preventing chlamydia.” 


At present, advanced cervicovaginal microbiome analysis is not available to most clinicians. But, said Dr. Burk, I can envision a scenario where it would be readily accessible to most doctors and perhaps even incorporated into home tests, like we have now for COVID-19.”  


“This study represents a breakthrough by showing that the risk posed by a relatively benign bacterial condition such as BV can be assessed through microbiome analysis,” says Mykhaylo Usyk, Ph.D., research assistant professor of pediatrics and of microbiology & immunology and first author of the paper. “Our findings suggest that only a subset of BV cases may require treatment to prevent subsequent infections with chlamydia.”  


Reference: Usyk M, Carlson L, Schlecht NF, et al. Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women. Cell.  2025:S0092867424014247. doi: 10.1016/j.cell.2024.12.011


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.